Monitor the HFSA meeting for any data disclosures or KOL feedback that could shift the probability of CardiAMP HF II success. The FDA's agreement that this single trial may suffice for approval is a positive regulatory signal, but no efficacy/safety data were released in this filing.
Price Chart
Executive Summary
BioCardia filed an 8-K announcing a poster presentation of the CardiAMP HF II trial design at the HFSA Annual Scientific Meeting (Oct 9-12, 2026). The press release notes that the FDA recently agreed the ongoing CardiAMP HF II trial may be sufficient to support approval. This is a routine scientific conference update with no new clinical data or financial results disclosed.
Key Facts
- BioCardia will present a scientific poster on the CardiAMP HF II trial design at the HFSA Annual Scientific Meeting in Phoenix, AZ from October 9-12, 2026.
- The FDA has agreed that the ongoing CardiAMP HF II trial may be sufficient to support FDA approval.
- The company is also advancing regulatory submissions with the FDA and Japan's PMDA.
- No new clinical data, financial results, or material financial terms were disclosed in the filing.
Financial Impact
No financial figures disclosed; this is a clinical trial design presentation with no revenue or cost impact reported.
Risk Factors
- Clinical trial failure or negative data from CardiAMP HF II could materially impair the stock.
- BioCardia's liquidity position and ability to raise additional funds remain risks as noted in the forward-looking statements.
- Regulatory approval is not guaranteed even if the trial design is accepted.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-032270 |
| Exhibit: ex_1023323.htm | 0001437749-26-032270 |
| Document: 0001437749-26-032270-index-headers.html | 0001437749-26-032270 |
| Document: 0001437749-26-032270-index.html | 0001437749-26-032270 |
| Document: 0001437749-26-032270.txt | 0001437749-26-032270 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9259 (+3.16%) |
Oct 19, 2026 8d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9259 (+2.88%) |
Oct 7, 2026 20d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9259 (−15.06%) |
Oct 1, 2026 26d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9259 (−9.23%) |
Oct 1, 2026 26d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9259 (−9.23%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9259 (−11.82%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9259 (−11.82%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9259 (−15.83%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9259 (−12.65%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9259 (−2.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers